- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01563367
A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof (CABG-01)
April 28, 2014 updated by: Pharmacosmos A/S
A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute CABG, Valve Replacement or a Combination Thereof
The purpose of the study is to demonstrate that intravenous iron isomaltoside 1000 (Monofer®) is superior compared to placebo with respect to increasing the haemoglobin level in non-anaemic patients undergoing cardiac surgery
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The role of preoperative haemoglobin as a predictor of short-term and long-term outcomes after cardiac surgery has been well established.
Anaemia can impede a patient's ability to recover fully and participate in postoperative rehabilitation.
It has been found that patients with a normal haemoglobin level may become anaemic during surgery.
An evaluation of patients undergoing cardiac surgery, i.e.
CABG, valve or combined CABG-valve procedures showed that there was a decrease in mean haemoglobin level pre-surgery two and four days after surgery.
To date, no prospective randomised clinical study in cardiac surgery assessing the effect of intravenous iron supplementation in patients undergoing cardiac surgery has been reported.
This prospective, randomized, placebo controlled, double blind study is planned to evaluate the effect of intravenous iron isomaltoside 1000 (Monofer®) in comparison with placebo in non-anaemic patients undergoing cardiac surgery.
Study Type
Interventional
Enrollment (Actual)
74
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Copenhagen, Denmark
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women, aged more than 18 years.
- Subjects undergoing elective or sub-acute CABG, valve replacement or a combination thereof
- Female Hb ≥ 12.0 g/dl (7.45 mmol/l), Male Hb ≥ 13.0 g/dl (8.1 mmol/l).
- Willingness to participate after informed consent.
Exclusion Criteria:
- Subjects receiving blood transfusion less than 30 days before screening and/or during the elective or sub-acute CABG, valve replacement, or a combination thereof.
- Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
- Serum Ferritin > 800 ng/ml.
- Known hypersensitivity to any excipients in the investigational drug products.
- Patients with a history of multiple allergies.
- Decompensated liver cirrhosis and hepatitis.
- Alanine Aminotransferase (ALT) > 3 times normal upper value.
- Acute infections (assessed by clinical judgement).
- Rheumatoid arthritis with symptoms or signs of active joint inflammation.
- Pregnant or nursing. (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, Intrauterine Devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
- Participation in any other clinical trial where the study drug has not passed five half-lives prior to screening.
- Untreated Vitamin B12 or folate deficiency.
- Other IV or oral iron treatment within 4 weeks prior to screening visit.
- Erythropoietin treatment within 4 weeks prior to screening visit
- Impaired renal function defined by se-creatinin > 150 µmol/l
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Iron isomaltoside 1000 (Monofer®)
Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion
|
All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
|
Placebo Comparator: 0,9% sodium saline
Placebo (0.9% sodium saline) - Intravenous infusion
|
All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in haemoglobin (Hb) concentrations
Time Frame: From t=0 to t=4 weeks postoperatively
|
To demonstrate that intravenous iron isomaltoside 1000 (Monofer®) is superior compared to placebo with respect to increasing the haemoglobin level in non- anaemic patients undergoing cardiac surgery
|
From t=0 to t=4 weeks postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hb concentrations
Time Frame: t=0, t=5 days and t=4 weeks
|
Proportion of patients that are anaemic (women < 12 g/dL and men < 13 g/dL) at day 5 and week 4
|
t=0, t=5 days and t=4 weeks
|
Number of patients in each randomisation group who need blood transfusion and number of transfusions administered
Time Frame: From t=0 to t=day 5 and t=4 weeks
|
To compare the number of patients who will need blood transfusion and number of transfusions in each randomisation group
|
From t=0 to t=day 5 and t=4 weeks
|
Change in concentrations of serum ferritin, serum iron and Transferrin Saturation (TfS) TfS, and reticulocytes
Time Frame: Change from baseline (preoperatively- the day before surgery or same day) in concentrations of serum ferritin, serum iron and Transferrin Saturation (TfS) TfS, and reticulocytes at 4 weeks and 3 months postoperatively
|
From t=0 to t=day 5 and t=4 weeks
|
Change from baseline (preoperatively- the day before surgery or same day) in concentrations of serum ferritin, serum iron and Transferrin Saturation (TfS) TfS, and reticulocytes at 4 weeks and 3 months postoperatively
|
Number of postoperative days to discharge
Time Frame: From t=0 to discharge
|
To compare the number of days to discharge between the 2 randomisation groups
|
From t=0 to discharge
|
Changes in New York Heart Association (NYHA) classification
Time Frame: From t=0 to t=4 weeks
|
To compare the changes in New York Heart Association (NYHA) classification from baseline to 4 weeks postoperatively
|
From t=0 to t=4 weeks
|
Number of patients in each randomisation group who experience any study drug related adverse events (AEs/SAEs/SUSARs)
Time Frame: From screening and until completion (t=-7 day and upto t=4 weeks)
|
To compare the number of study drug related adverse events (AEs/SAEs/SUSARs) between subjects treated with iron isomaltoside 1000 (Monofer®) infusion and subjects treated with placebo infusion
|
From screening and until completion (t=-7 day and upto t=4 weeks)
|
Change in Hb
Time Frame: t=0, t=day 5 and t=week 4
|
Proportion of patients able to maintain Hb between 9.5 and 12.5 g/dL (both values included) at day 5 and week 4
|
t=0, t=day 5 and t=week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Lars Lykke Thomsen, Pharmacosmos A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
September 1, 2013
Study Registration Dates
First Submitted
March 16, 2012
First Submitted That Met QC Criteria
March 22, 2012
First Posted (Estimate)
March 27, 2012
Study Record Updates
Last Update Posted (Estimate)
April 29, 2014
Last Update Submitted That Met QC Criteria
April 28, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-CABG-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-anaemic Patients Undergoing Cardiac Surgery
-
Vanderbilt UniversityGE HealthcareCompletedPatients Undergoing Cardiac SurgeryUnited States
-
University of LuebeckCompletedPatients Undergoing Cardiac Surgery
-
Centre Hospitalier Universitaire DijonCompletedPatients Undergoing Cardiac Surgery | Patients With Coronary Artery Bypass Surgery With CECFrance
-
Seoul National University HospitalWithdrawnPatients Undergoing Cardiac Surgery Using Cardiopulmonary BypassKorea, Republic of
-
Yonsei UniversityCompletedPatients Undergoing Cardiac Surgery With Cardiopulmonary BypassKorea, Republic of
-
Shaare Zedek Medical CenterUnknownPatients Undergoing Open Heart Surgery | Patients Undergoing Lung SurgeryIsrael
-
Philipps University Marburg Medical CenterRecruitingPatients Undergoing SurgeryGermany
-
Yonsei UniversityUnknownPatients Undergoing SurgeryKorea, Republic of
-
Gangnam Severance HospitalCompletedPatients Undergoing Spine SurgeryKorea, Republic of
-
Hospital for Special Surgery, New YorkCompletedPatients Undergoing Ankle SurgeryUnited States
Clinical Trials on Iron isomaltoside 1000 (Monofer®)
-
Pharmacosmos A/SMax NeemanCompleted
-
Pharmacosmos UK LtdBioStataCompletedIron Deficiency AnaemiaUnited Kingdom
-
Pharmacosmos A/SBioStataCompletedIron Deficiency AnemiaDenmark
-
Pharmacosmos A/SCompleted
-
Pharmacosmos A/SCompletedInflammatory Bowel DiseaseDenmark
-
Yonsei UniversityCompletedComplex Valvular Heart SurgeryKorea, Republic of
-
Pharmacosmos A/SCompletedPatients With Chemotherapy Induced Anemia (CIA)United States
-
Pharmacosmos A/SCompletedAnemia | Iron Metabolism Disorders | Deficiency Diseases | Anemia, Iron Deficiency | Hematologic DiseaseJapan
-
Pharmacosmos A/SCompletedIron Deficiency Anemia | Iron Deficiency AnaemiaUnited States
-
Nottingham University Hospitals NHS TrustPharmacosmos A/SUnknownAnemia | Gastric Cancer | Esophageal CancerUnited Kingdom